HOME >> BIOLOGY >> NEWS
Obesity Gene: Possible Link To Heart Disease Risk

DALLAS, June 12 -- A link has been found between leptin, a protein product of the obesity gene, and risk for coronary heart disease, the cause of heart attacks, say researchers in a study published today in an American Heart Association journal.

The obesity gene was cloned in 1994. Its product, leptin, acts as a signal to help the body decide when it has eaten enough food to feel full. The amount of leptin in the blood has been directly linked to body fat.

This study is the first to associate leptin elevations in the blood with so-called insulin resistance syndrome. The syndrome -- characterized by high blood pressure, low levels of the "good" high-density lipoprotein cholesterol and elevations in insulin -- sets the stage for heart disease. Insulin is a hormone that helps the body use glucose, its main fuel. An excess of insulin (a condition called insulin resistance) indicates the body is not processing glucose normally.

The study was conducted by researchers in the Wynn department of metabolic medicine of the Imperial College School of Medicine, London.

In the study, which appears in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association, researchers measured blood leptin levels in 74 men. They found that the higher the level of leptin the more likely the men were to have the syndrome, and thus "perhaps a greater heart disease risk," says Francisco Leyva, M.D., specialist registrar in cardiology at Charing Cross Hospital.

"We have found that leptin concentrations are related to the metabolic disturbances that constitute the syndrome, especially insulin resistance," says Leyva. "Futher studies are needed to determine whether insulin and leptin play a coordinating role in this syndrome and whether leptin concentrations could provide an additional measure of heart risk.

"Measuring leptin might become a new way to determine a person's risk of heart dis
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-706-1279
American Heart Association
11-Jun-1998


Page: 1 2

Related biology news :

1. Obesity and hypertension: Two epidemics or one?
2. Obesity alone not a good predictor of cardiovascular risk and death, fat distribution proved best
3. Obesity drug inhibits prostate tumor growth
4. Obesity and blood pressure
5. Obesity, kidney genetics, erectile dysfunction among highlighted research at APS Meeting
6. Obesity in Costa Rican children alarming, likely future health burden
7. Obesity prevention program aimed at second graders
8. Obesity not a personal failing, but a battle against biology
9. Obesity sleuths find chronic diseases linked to behavior contrary our DNA
10. Obesity...by choice
11. Obesity may exacerbate a heart disorder in African American females

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Obesity Gene Possible Link Heart Disease Risk

(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider ... with a team of researchers from Yale University’s School ... Collaborative to provide electronic questionnaire data collection through use ... started in May, aims to evaluate the impact of ... to and participation in urban agriculture to impact their ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
Cached News: